Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MY009212A
- Development stage
- Unknown
- Lead developer
- Wuhan Createrna Science and Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MY009212A is a small molecule drug in clinical development as an oral pantetheinase (vanin 1) inhibitor. Its primary mechanism of action is the inhibition of pantetheinase, an enzyme implicated in inflammatory processes. The drug is being developed for the treatment of inflammatory bowel diseases (IBD), with its main therapeutic area being digestive system disorders. As of March 2025, it has completed Phase 1 clinical trials evaluating safety, tolerability, and pharmacokinetics in healthy adult volunteers. The originator and active developer is Shanghai Meiyue Biotech Development Co., Ltd., with involvement from Createrna Development Co., Ltd.[1][2][3]
02
Targets
VNN1 (Vanin-1)
Beyond the preview
Go deeper on MY009212A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MY009212A.